These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28276855)

  • 21. A practical guide to selecting and using new ulcerative colitis therapies.
    Nagaraj T; Shinn J; De Felice K
    Curr Opin Gastroenterol; 2024 Jul; 40(4):235-242. PubMed ID: 38606783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report.
    Xu X; Jiang JW; Lu BY; Li XX
    World J Clin Cases; 2024 Mar; 12(9):1685-1690. PubMed ID: 38576732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective Management of XLA Associated Enteropathy with Vedolizumab Monotherapy.
    Rai E; Doroudchi A; Nulsen B; Younes R; Kuo CY
    J Clin Immunol; 2024 Jun; 44(7):150. PubMed ID: 38896327
    [No Abstract]   [Full Text] [Related]  

  • 24. Serious Infections in Offspring Exposed in Utero to Vedolizumab.
    Gorodensky JH; Bernatsky S; Afif W; St-Pierre Y; Filion KB; Vinet É
    Inflamm Bowel Dis; 2024 Mar; 30(3):496-498. PubMed ID: 37172205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vedolizumab, an α4β7-Integrin Inhibitor, Exacerbates Ulcerative Colitis-Related Spondylitis.
    Yamamoto H; Taniguchi Y
    J Clin Rheumatol; 2024 Oct; 30(7):e161. PubMed ID: 38982566
    [No Abstract]   [Full Text] [Related]  

  • 26. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
    Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
    Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
    Bye WA; Jairath V; Travis SPL
    Aliment Pharmacol Ther; 2017 Jul; 46(1):3-15. PubMed ID: 28449273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.
    Dart RJ; Samaan MA; Powell N; Irving PM
    Clin Exp Gastroenterol; 2017; 10():57-66. PubMed ID: 28424557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
    J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
    Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.
    Navaneethan U; Edminister T; Zhu X; Kommaraju K; Glover S
    Inflamm Bowel Dis; 2017 Apr; 23(4):E17. PubMed ID: 28296827
    [No Abstract]   [Full Text] [Related]  

  • 33. Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.
    Engel T; Ungar B; Yung DE; Ben-Horin S; Eliakim R; Kopylov U
    J Crohns Colitis; 2018 Jan; 12(2):245-257. PubMed ID: 29077833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.
    Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G
    J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
    Allegretti JR; Barnes EL; Stevens B; Storm M; Ananthakrishnan A; Yajnik V; Korzenik J
    Dig Dis Sci; 2017 Jun; 62(6):1590-1596. PubMed ID: 28357697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
    Wright AP; Fontana RJ; Stidham RW
    Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
    Zundler S; Neurath MF
    Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Gagniere C; Bouhnik Y;
    Aliment Pharmacol Ther; 2017 Aug; 46(3):310-321. PubMed ID: 28593685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
    Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
    J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.